Bo Liang personal email
- Valid
- Valid
- Valid
- Valid
- Valid
Bo Liang phone numbers
Dr. Bo Liang is a serial entrepreneur and an experienced scientist with extensive experience in pharmaceutical drug development and chemical/composite materials industry. Dr. Liang is currently Co-founder, Chairman & CEO of IVIEW Therapeutics Inc. IVIEW Therapeutics Inc. is a clinical-stage ophthalmology-focused therapeutics company based in Cranbury, New Jersey committed to the treatment of ocular diseases with high unmet medical needs through innovative small molecule drugs and gene therapy approaches. Our focus on novel mechanisms of action combined with our proprietary drug delivery technology platforms allows us to bring forward highly differentiated assets with potentially superior target product profiles. Currently, our portfolio includes novel products to treat Acute Infectious Conjunctivitis, Dry Eye Disease (DED), Myopia, presbyopia and Glaucoma.IVIEW has built an exceptional team with ophthalmologists, pharmaceutical experts with entrepreneurial experience to execute on its drug development programs. IVIEW’s strategy has been externally validated with an investment of over $40M in three tranches from well-known VCs.Dr. Liang also co-founded Adesso Advanced Materials in 2010. Adesso invented the first recyclable epoxies in the world and "Recycloset and Cleavamine" were recognized as the JEC-Asia 2012 Innovation Award and 2016 & 2017 US TechConnect National Innovation Award. Prior to that, Dr. Liang was Executive Vice President at Foresight Biotherapeutics in New York city. In 2006, Dr. Liang co-founded CLS Pharmaceuticals and managed R&D and advanced the development of an eye drug into phase II clinical trials, leading to out-license to Foresight, which later was acquired by Shire in 2015 with $300m cash after a successful phase II trial of the program. Dr. Liang was a Senior Scientist at Pharmacopeia where he spent six years in drug discovery and advanced a novel drug candidate from research to clinical trials to treat human respiratory disease. Before he came to US, Dr. Liang had 3 years entrepreneurial and marketing experience in Beijing, China.Dr. Liang held over fifty issued or pending US and international PCT patents. He has published over 15 articles in various scientific journals and has served as a reviewer for Bioorganic & Medicinal Chemistry.
Iview Therapeutics Inc.
-
Chairman & CeoIview Therapeutics Inc. Jun 2018 - Present
-
Co-Founder, Director & PresidentIview Therapeutics Inc. Aug 2015 - Jun 2021Specialty Biotechnology firm focusing on topical drug and medical device development with specialization focus on specific therapeutic areas (i.e. ophthalmology, dermatology, Otolaryngology, Gynecology)IVIEW Therapeutics develops long-acting povidone iodine ophthalmic drops for the treatment of active infections of the conjunctiva and cornea by bacteria, mycobacteria, virus, fungus, or amoebic causes. The lead compound, IVIEW-1201 is an extended release in-situ gel povidone iodine composition which exhibits sol-to-gel phase transitions when instilling into the eye. The effective concentration of povidone iodine is maintained by the equilibrium between solution and the gel bound components resulting in a long lasting anti-viral, antimicrobial, and less irritation effect. We plan to move the drug candidate into physician sponsored proof-of-concept clinical trials in 2017. We have completed pre-clinical studies of IVIEW-1201 and have demonstrated CMC stability, in-vitro and in-vivo antimicrobial, antifungal, anti-viral efficacy and also minimized irritation in Rabbit tolerability studies. There is currently no broadly effective therapy that treats all causes of infection and nothing is approved for the treatment of viral conjunctivitis. This represents a massive unmet need in ophthalmology.
-
Co-Founder, ChairmanAdesso Advanced Materials Apr 2010 - Jun 2018Adesso Advanced Materials is a US-China joint venture started in New York in 2009 and it has set up its R&D center in Wuxi, China since 2010. Adesso has successfully developed revolutionary re-workable and recyclable epoxy resin systems, i.e. the Recycloset, which are particularly designed for manufacturing the next generation sustainable fiber reinforced epoxy composites. RecyclosetTM technology is based on our patent-pending curing agents, i.e. Cleavamine.Unlike conventional epoxy resin systems and formulas, fiber composites made from our proprietary Recycloset systems can be degraded under specific condition, at atmospheric pressure and below 150℃. 95% of the original fiber reinforcing materials (e.g. carbon fiber, glass fiber, synthetic fiber and natural fiber, etc) can be recovered and recycled at the end of their service life time. The texture and mechanical properties of the recovered fiber materials are maintained. Thus, the recycled fiber material could be re-used in manufacturing new epoxy composite products. In addition, the degraded epoxy polymers can also be recovered, and used as polymer materials for special applications.Owing to this revolutionary innovation, Adesso Advanced Materials won JEC ASIA 2012 Innovation Award in the Category of Recycling on June 26 2012 in Singapore. Now Adesso has operations in China, US and UK. Its Shanghai, China R&D center and Princeton, NJ, US Lab are focusing on Cleavamine curing agent chemistry research, process development and composite recycling technology development, while its Wuhu, Anhui center is focusing on resin formulation product development, composite application research, and formulated resin manufacturing. Adesso's EU operation was set up in 2013 in Cambridge, UK for business development of EU market. We are now actively working with strategic collaborative partners to co-develop and broaden the applications of our proprietary technologies and products.
-
ChairmanJiangsu Deda Pharmaceuticals Feb 2010 - Dec 2015
-
Executive Vice President, Pharmaceutical DevelopmentForesight Biotherapeutics, Inc. May 2008 - May 2010responsible for overseeing contract pharmaceutical R&D and manufacturing, managing the company’s intellectual property portfolio, and assisting in due diligence for in-licensing opportunities for the company. After completing Phase II trial of its lead program FST-100 for the treatment of viral conjunctivitis, Foresight Biotherapeutics was acquired by Shire plc for $300 million cash in August 2015.
-
Founder, PresidentEcophalanx, Inc. Oct 2006 - May 2008Oversee operation, legal, contract and financial control of the companyAssist in developing e-commerce on-line ordering and marketing to provide reversing drops to physiciansAssist in managing collaborations with compounding pharmacies and eye supply marketers.
-
Co-Founder, Executive Vice President & CooCls Pharmaceuticals, Inc. Oct 2005 - May 2008Managed R&D work, and developed an ophthalmic product into human phase III clinical trials
-
Senior ScientistPharmacopeia Jun 2001 - May 2007UsLed a chemistry team in the project and advanced one drug candidate from research into human clinical trials, resulting in $2 million milestone payment from Schering Plough Research Institute
Bo Liang Skills
Bo Liang Education Details
-
University Of PennsylvaniaOrganic Chemistry -
Nyu Stern School Of BusinessBusiness Administration
-
Peking UniversityChemistry
Frequently Asked Questions about Bo Liang
What company does Bo Liang work for?
Bo Liang works for Iview Therapeutics Inc.
What is Bo Liang's role at the current company?
Bo Liang's current role is Chairman & CEO, IVIEW Therapeutics Inc..
What is Bo Liang's email address?
Bo Liang's email address is ch****@****ail.com
What is Bo Liang's direct phone number?
Bo Liang's direct phone number is +160989*****
What schools did Bo Liang attend?
Bo Liang attended University Of Pennsylvania, Nyu Stern School Of Business, Peking University.
What are some of Bo Liang's interests?
Bo Liang has interest in Management, Travel, Entrepreneurship.
What skills is Bo Liang known for?
Bo Liang has skills like Drug Discovery, R&d, Pharmaceutical Industry, Patents, Drug Development, Business Development, Clinical Trials, Clinical Development, Chemistry, Hplc, Biochemistry, Strategy.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial